Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 44370 TA in Acute Migraine
NCT00751803Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2008
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of BI 44370 in migraine (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Pain free response at 2 hours. Started Aug 2008; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00751803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00751803.